The clinical and cost effectiveness of immunizing children WIth PCV7 and PCV13 is well established in the scientific literature. However the success of pneumococcal conjugate vaccines in children has given rise to questions from payers regarding whether continued investment in PCV13 for children is needed. The proposed research project undertaken by the intern will help the partner organization to quantitatively determine: 1) What is the optimal percentage of the children population that needs to be vaccinated to incure herd immunity in the rest of the population? 2) If vaccinating children with PCV13 were discontinued, how fast will herd immunity decay? and 3) If cavvination of children with PCV13 were discontinued, how fast will previously protected serotypes return to the population? Answers to these questions will inform the partner oganization for make evidence-based decisions on the PCV13 vaccination program.
Dr. Michael Li
Rebecca de Boer
Institute of Health Economics
Finance, insurance and business
University of Alberta
Find the perfect opportunity to put your academic skills and knowledge into practice!Find Projects
The strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.